With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases like hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis with an eye toward broader patient populations.

Analysts said the development marked a key milestone for Intellia and the broader gene editing field, as it points to FDA’s increased willingness to allow trials for gene therapies.